Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jcv.2021.104912 http://scihub22266oqcxt.onion/10.1016/j.jcv.2021.104912 34298379!8282447!34298379     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Virol 2021 ; 142 (ä): 104912 Nephropedia Template TP {{tp|p=34298379|t=2021. Emerging SARS-CoV-2 variant B 1 1 7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 |pdf=|usr=}}{{34298379}} gab.com Text Emerging SARS-CoV-2 variant B 1 1 7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 JO: J Clin Virol http://www.kidney.de/pget.php?&tw=1&pmid=34298379 #FOAvip Spike-specific antibodies contribute significantly to the neutralising activity against SARS-CoV-2 and are important for the therapeutic effect of convalescent plasma. B.1.1.7 is a recently emerged variant of SARS-CoV-2 that has several mutations in the gene encoding for the spike-protein. To assess the potential effect these mutations could have on the neutralising efficacy of antibodies, we evaluated 96 serum samples from convalescent plasma donors collected before the first occurrence of B.1.1.7 and tested their neutralising effect on wild-type SARS-CoV-2 and B.1.1.7. We found that B.1.1.7 is more resistant to neutralisation by convalescent plasma from patients infected with wild-type SARS-CoV-2 with an overall decrease in neutralising activity of 47.7%. Thus, the neutralising effect of convalescent plasma should be determined against the major circulating virus clades whenever possible to ensure the best possible therapeutic effect. Twit Text FOAVip Emerging SARS-CoV-2 variant B 1 1 7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 ????J Clin Virol http://www.kidney.de/pget.php?&tw=1&pmid=34298379 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34298379 #FOAvip English Wikipedia <ref>{{Cite pmid|34298379}}</ref> Emerging SARS-CoV-2 variant B 1 1 7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2 #MMPMID34298379 Muller K; Girl P; Giebl A; von Buttlar H; Dobler G; Bugert JJ; Gruetzner S; Wolfel R J Clin Virol 2021[Sep]; 142 (ä): 104912 PMID34298379show ga Spike-specific antibodies contribute significantly to the neutralising activity against SARS-CoV-2 and are important for the therapeutic effect of convalescent plasma. B.1.1.7 is a recently emerged variant of SARS-CoV-2 that has several mutations in the gene encoding for the spike-protein. To assess the potential effect these mutations could have on the neutralising efficacy of antibodies, we evaluated 96 serum samples from convalescent plasma donors collected before the first occurrence of B.1.1.7 and tested their neutralising effect on wild-type SARS-CoV-2 and B.1.1.7. We found that B.1.1.7 is more resistant to neutralisation by convalescent plasma from patients infected with wild-type SARS-CoV-2 with an overall decrease in neutralising activity of 47.7%. Thus, the neutralising effect of convalescent plasma should be determined against the major circulating virus clades whenever possible to ensure the best possible therapeutic effect. |*COVID-19/therapy[MESH] |*SARS-CoV-2[MESH] |Antibodies, Neutralizing[MESH] |Antibodies, Viral[MESH] |COVID-19 Serotherapy[MESH] |Humans[MESH] |Immunization, Passive[MESH]Emerging SARS-CoV-2 variant B 1 1 7 reduces neutralisation activity of(epmc).pdf DeepDyve Pubget Overpricing